MedTrace Logo

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

NCT01127893 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-03-10

Study results available
· View outcomes & findings →

Summary

An evaluation of the long term safety of tanezumab when administered by subcutaneous injection every 8 weeks for up to 64 weeks

Conditions

Interventions

BIOLOGICAL

Tanezumab

Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

BIOLOGICAL

Tanezumab

Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

BIOLOGICAL

Tanezumab

Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-15
Primary Completion
2010-09-29
Completion
2010-09-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127893 on ClinicalTrials.gov